Hyalo Technologies

What Hyalo Technologies does

Hyalo Technologies, LLC is a privately held biotechnology and pharmaceutical company founded in 2013 and headquartered in Somerset, New Jersey. The company develops two proprietary technology platforms: (1) HyaloSphere, a controlled-release drug delivery system built on proprietary nanotechnology that enables target-specific delivery, time-controlled and sequential release, and 100% biodegradability; and (2) the Hyalo Sterilization Matrix, a low-temperature sterilization method that preserves product integrity, enables room-temperature storage, and eliminates cold-chain logistics for pharmaceuticals, biologics, antibodies, biosimilars, and medical devices. The USPTO granted Hyalo a patent for the 'Method of Sterilization of Microparticles' on November 3, 2020.

The company serves pharmaceutical companies, biotechnology companies, and medical device manufacturers — the primary customers being pharma and biotech firms seeking advanced delivery and stabilization solutions. Hyalo does not commercialize through a direct sales force; it operates a B2B licensing model, pursuing strategic partnerships, joint ventures, and technology licensing agreements with manufacturers for global distribution. Pricing is negotiated on a deal-by-deal basis and is not publicly disclosed. The company has 11–50 employees and operates with a lean, founder-led structure; Shalabh Jain serves as Chairman, CEO, and Founder, with Dr. Sanjay Jain as Co-Founder and Vice-Chairman. Bob Oliver (former Chairman & CEO of Otsuka Pharmaceutical Companies) sits on the board as Executive Advisor.

No external funding rounds, institutional investors, or named commercial partners are disclosed in the available data, and no revenue figures have been reported. The company appears to be in the platform-validation and early commercialization phase, relying on its patent portfolio, scientific advisory board, and partnership outreach as primary commercial assets.

Name

Hyalo Technologies

Legal name

Hyalo Technologies, LLC

Website

https://hyalotechnologies.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Hyalo Technologies is a private biotech and pharmaceutical company developing proprietary nanotechnology drug delivery (HyaloSphere) and low-temperature sterilization (Hyalo Sterilization Matrix) platforms, licensing them to pharmaceutical, biotech, and medical device manufacturers through strategic partnerships and joint ventures.

Ownership category

akta.pro rank

Product category

Pharmaceutical Drug Delivery Technology

NAICS

Research and Development in Nanotechnology (541713), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies (HLAAAJAN)

akta.pro secondary industry

Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low) (HLAGAGAK)

Keywords

• Drug delivery systems
• Nanopharmaceutical technology
• Biologics sterilization
• Controlled release drugs
• Pharmaceutical R&D services

Headquarters

HQ city

Somerset

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Product Development and Licensing: The company develops proprietary drug delivery technologies and seeks to commercialize through strategic partnerships, joint ventures, and licensing agreements with pharmaceutical and biotech companies for global distribution of products.
2. Technology Licensing: Licensing their HyaloSphere nanotechnology platform and Hyalo Sterilization Matrix to pharmaceutical manufacturers for use in developing new drug products.
3. Sterilization Technology Licensing: Licensing the Hyalo Sterilization Matrix technology to biopharmaceutical companies to enable room temperature storage and eliminate cold chain logistics.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Hyalo Technologies develops and licenses two proprietary technology platforms: HyaloSphere with NanoSphere technology, a controlled-release drug delivery system using proprietary nanotechnology for target-specific, time-controlled, and sequential drug release with 100% biodegradability; and Hyalo Sterilization Matrix, a low-temperature sterilization method for pharmaceuticals, biologics, antibodies, biosimilars, and medical devices that maintains product integrity and enables room-temperature storage. The company commercializes these technologies through licensing and strategic partnerships with pharmaceutical and biotech manufacturers rather than direct product sales.

Product overview

Hyalo Technologies offers two core proprietary products: HyaloSphere with NanoSphere technology as a controlled release drug delivery system for various applications including chemoembolization, topical formulations, vaccine delivery, and injectables; and the Hyalo Sterilization Matrix which enables sterilization of pharmaceutical products at lower temperatures while maintaining stability and efficacy, eliminating the need for cold chain logistics. Together, these products address drug delivery challenges and product stabilization in the biopharmaceutical industry.

Differentiator

Problem solved

Functional benefit

Brands

• HyaloSphere: A uniquely designed controlled release drug delivery system using proprietary NanoSphere technology for overcoming problems of conventional therapy and enhancing therapeutic efficacy of drugs. Applications include chemoembolization, topical formulations, vaccine delivery, injectables, dermatology, biologics, antibodies, biosimilars, pain management, anticoagulants, diabetic medications, antibiotics, and cosmetics.
• Hyalo Sterilization Matrix

Products and services

• HyaloSphere with NanoSphere Technology A uniquely designed controlled release drug delivery system using proprietary nanotechnology that delivers drugs directly to targeted sites with time-controlled and sequential release and 100% biodegradability. Applications span chemoembolization, topical formulations, vaccine delivery, injectables, dermatology, biologics, antibodies, biosimilars, pain management, anticoagulants, diabetic medications, antibiotics, and cosmetics. Intended for pharmaceutical and biotechnology partners.
• Hyalo Sterilization Matrix A sterilization method that adds a matrix to pharmaceutical products and medical devices, sterilizing them at lower temperatures while preventing product denaturation, maintaining efficacy, and enhancing stability. Enables room-temperature storage and transport, eliminating cold chain logistics. USP patent for Method of Sterilization of Microparticles granted November 2020. Intended for biopharmaceutical and medical device manufacturers.

Quantifiable outcome

• Elimination of cold chain logistics requirements
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Pharmaceutical CompaniescoreStrategic or Co-development PartnerHyalo Technologies seeks strategic partnerships with pharmaceutical companies to develop and commercialize products using their proprietary drug delivery technologies. The company aims to establish joint ventures to produce and distribute innovative healthcare products in the U.S. and globally to address unmet healthcare needs.
• Biotechnology CompaniescoreStrategic or Co-development PartnerPartnerships with biotech companies to develop and commercialize biologics, antibodies, biosimilars, and other complex therapeutics using Hyalo Technologies' advanced drug delivery platforms and stabilization technologies.
• Manufacturing-based CompaniesminorStrategic or Co-development PartnerOpen to joint ventures and collaborations with manufacturing companies to produce and market innovative healthcare products globally.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Emerging players

• CytImmune Sciences: Clinical-stage oncology biotech developing tumor-targeted gold nanoparticle drug delivery platforms. Comparable to Hyalo as a nanotechnology-based targeted drug delivery platform focused on oncology applications like chemoembolization.
• Crystal Genomics / Cristal Therapeutics: European nanomedicine company developing polymeric nanoparticle drug delivery platforms for oncology. Overlaps with Hyalo's nanoparticle drug delivery IP focus and pharma partnership business model.

Direct peers

• Selecta Biosciences: Clinical-stage biotech developing synthetic nanoparticle-based immunomodulatory therapies and tolerogenic antigen-specific therapies. Overlaps with Hyalo's nanoparticle drug delivery IP and strategic pharma partnership approach.
• Halozyme Therapeutics: Commercial-stage biotech whose Enhanze platform is a proprietary drug delivery technology enabling subcutaneous delivery of biologics. Comparable to Hyalo as a licensing-led drug delivery platform licensing into large pharma.
• Alkermes: Profitable CNS-focused pharma whose business is built on proprietary drug delivery and formulation platforms that extend the lifecycle of partner molecules. Operates in the same drug delivery platform-licensing category as Hyalo.
• Camurus: Specialty pharma based on its FluidCrystal nanotech depot drug delivery platform for sustained release of injectable therapeutics. Closely comparable to HyaloSphere as a nanotechnology-based controlled-release delivery company.

Broad incumbents

• West Pharmaceutical Services: Global market leader in elastomer components and drug delivery containment systems for injectable therapies. Compares to Hyalo across the injectables/biologics delivery value chain with particular overlap on stabilization of sensitive molecules.
• Pacira BioSciences: Specialty pharma commercializing DepoFoam, a multivesicular liposome controlled-release delivery platform. Direct overlap with Hyalo's controlled-release drug delivery thesis but at a much larger commercial scale.
• Catalent: Large global CDMO offering advanced drug delivery and formulation services including nanoparticle and biologics platforms, serving pharma and biotech across thousands of programs. Compares to Hyalo on delivery technology but at vastly broader scale.
• Evonik Health Care: Specialty division of a major chemical company supplying functional excipients, polymers, and biodegradable delivery systems used in injectables and controlled-release formulations. Highly comparable as a supplier/licensor of drug delivery materials.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/hyalotech

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hyalo Technologies